Sökning: "Joachim Gullbo"

Visar resultat 1 - 5 av 6 avhandlingar innehållade orden Joachim Gullbo.

  1. 1. Preclinical Development of New Alkylating Oligopeptides for Cancer Therapy

    Författare :Joachim Gullbo; Rolf Larsson; Peter Nygren; Staffan Eriksson; Uppsala universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Pharmacology; pharmacology; oncology; chemistry; Melphalan derivatives; Farmakologi; Pharmacological research; Farmakologisk forskning;

    Sammanfattning : Oligopeptides can be used to carry cytotoxic agents in cancer chemotherapy, using tumour-associated proteins as the molecular target for selectivity. During the seventies and eighties Peptichemio, a cocktail of six alkylating oligopeptides carrying m-L-sarcolysin, was investigated in a wide variety of human malignancies. LÄS MER

  3. 2. Studies of Cytotoxic Compounds of Natural Origin and their Mechanisms of Action

    Författare :Jenny Felth; Lars Bohlin; Joachim Gullbo; Ulf Göransson; Thomas Efferth; Uppsala universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; cytotoxic; cardiac glycoside; gambogic acid; cancer; mechanism of action; Pharmacognosy; Farmakognosi; Pharmacognosy; Farmakognosi;

    Sammanfattning : Cancer incidence is increasing and novel anticancer drugs with new mechanisms of action are essential for future chemotherapeutic treatment. Natural products have historically played an important role in the development of anti-cancer drugs and have potential to do so also in the future. LÄS MER

  4. 3. Prognostic Biomarkers and Target Proteins for Treatment of High-grade Gliomas

    Författare :Linda Sooman; Simon Ekman; Johan Lennartsson; Joachim Gullbo; Michael Bergqvist; Erik Blomquist; Stefan Bergström; Beatrice Melin; Uppsala universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; High-grade glioma; prognostic biomarkers; combination chemotherapy; DNA methylation; FGF2; p38 MAPK; PTPN6; camptothecin; imatinib; vandetanib; EGFR; RAC1; Notch; Medical Science; Medicinsk vetenskap; Oncology; Onkologi;

    Sammanfattning : The survival for high-grade glioma patients is poor and the treatment may cause severe side effects. A common obstacle in the treatment is chemoresistance. To improve the quality of life and prolong survival for these patients prognostic biomarkers and new approaches for chemotherapy are needed. LÄS MER

  5. 4. Anticancer Activity of Melflufen : Preclinical Studies of a Novel Peptidase-Potentiated Alkylator

    Författare :Sara Strese; Joachim Gullbo; Rolf Larsson; Mårten Fryknäs; Sigurd Vitols; Uppsala universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; cancertherapy; preclinical studies; melflufen; aminopeptidase-potentiated; cancer; angiogenesis; Klinisk farmakologi; Clinical Pharmacology;

    Sammanfattning : Melflufen (melphalan flufenamide, chemical name L-melphalanyl-p-L-fluorophenylalanine ethyl ester hydrochloride, previously called J1) is a derivative of the classical alkylating agent melphalan. Melflufen is potentiated by hydrolytic cleavage by aminopeptidase N (APN), leading to high intracellular concentrations of alkylating moieties and subsequent cell death. LÄS MER

  7. 5. Preclinical Studies of the Melphalan Prodrug J1 for Cancer Therapy

    Författare :Malin Wickström; Joachim Gullbo; Rolf Larsson; Johan Hansson; Uppsala universitet; []
    Nyckelord :Pharmacology; Pharmacology; Chemotherapy; Melphalan prodrug; Cancer; Farmakologi;

    Sammanfattning : J1 (L-melphalanyl-L-p-fluorophenylalanyl ethyl ester) is a dipeptide derivative of the alkylating agent melphalan with increased cytotoxicity. In this thesis the preclinical pharmacology of J1 has been characterized.Our results show that J1 rapidly enters the cells, where melphalan is released by hydrolysis. LÄS MER